Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 3;14(9):1863.
doi: 10.3390/pharmaceutics14091863.

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Dara Kusic  1 , Jessica Heil  1   2 , Stefan Zajic  1   3 , Andrew Brangan  1   4 , Oluseun Dairo  1   5 , Gretchen Smith  1 , Diego Morales-Scheihing  1 , Russell J Buono  5 , Thomas N Ferraro  5 , Rachel Haroz  2   5 , Matthew Salzman  2   5 , Kaitlan Baston  2   5 , Elliot Bodofsky  2   5 , Michael Sabia  2   5 , Alissa Resch  1 , Laura B Scheinfeldt  1
Affiliations

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Dara Kusic et al. Pharmaceutics. .

Abstract

Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.

Keywords: OUD; chronic pain; opioid; pharmacogenetic.

PubMed Disclaimer

Conflict of interest statement

S.Z. is an employee of GSK and holds stock shares in GSK.

Figures

Figure 1
Figure 1
Visualization of participant response to “Genetics have the potential to improve my medical care”. The X-axis displays the range of potential statement responses, and the Y-axis displays the number of participants that chose a given response. GOALS participants are shaded in dark blue and OPTIN participants are shaded in aqua.
Figure 2
Figure 2
Visualization of the number of medications prescribed at baseline. The left panel displays the number of prescribed baseline opioid pain medications that require CYP2D6 for metabolism, the middle panel displays the number of prescribed baseline opioid pain medications that do not require CYP2D6 for metabolism, and the right panel displays the number of prescribed non-opioid pain medications. PM denotes poor metabolizer, IM denotes intermediate metabolizer, NM denotes normal metabolizer, and UM denotes ultra-rapid metabolizer. Each plotted box ranges from the 25th to the 75th percentile of the distribution. Whiskers extend in either direction to 1.5 times the interquartile range from each end of the box, or to the most extreme data point, whichever is less extreme.
See this image and copyright information in PMC

References

    1. Heil J., Zajic S., Albertson E., Brangan A., Jones I., Roberts W., Sabia M., Bodofsky E., Resch A., Rafeq R., et al. The Genomics of Opioid Addiction Longitudinal Study (GOALS): Study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder. BMC Med. Genom. 2021;14:16. doi: 10.1186/s12920-020-00837-3. - DOI - PMC - PubMed
    1. Scheinfeldt L.B., Brangan A., Kusic D.M., Kumar S., Gharani N. Common Treatment, Common Variant: Evolutionary Prediction of Functional Pharmacogenomic Variants. J. Pers. Med. 2021;11:131. doi: 10.3390/jpm11020131. - DOI - PMC - PubMed
    1. Relling M.V., Evans W.E. Pharmacogenomics in the clinic. Nature. 2015;526:343–350. doi: 10.1038/nature15817. - DOI - PMC - PubMed
    1. Bank P.C.D., Swen J.J., Guchelaar H.J. Implementation of Pharmacogenomics in Everyday Clinical Settings. Adv. Pharmacol. 2018;83:219–246. doi: 10.1016/bs.apha.2018.04.003. - DOI - PubMed
    1. Gharani N., Keller M.A., Stack C.B., Hodges L.M., Schmidlen T.J., Lynch D.E., Gordon E.S., Christman M.F. The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Med. 2013;5:93. doi: 10.1186/gm499. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources